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Abstract 
 
Poly-therapy is often prescribed for the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients. The numerous 
drugs are needed to treat COPD and also its comorbidities. Medicines needed to treat comorbid conditions add to the daily cost 
of COPD care. This study evaluates the costs of all reimbursed drugs used from Albanian outpatients with COPD over a year, 
in order to highlight the impact of non-respiratory drugs. Methods The data on costs of all reimbursed drugs used in 2012 from 
insured COPD outpatients were obtained from Health Insurance Institute database. Drugs and their costs were divided 
according to the first level (main anatomical group) and the second level (main therapeutic group) of International Anatomical 
Therapeutic Chemical (ATC) classification system. All the data are calculated with Microsoft Office Excel program. Results In 
2012 non-respiratory drugs represented 45% of total drug reimbursement for Albanian outpatients with COPD. More expensive 
drugs were the ones acting on: Cardiovascular system (57% of non-respiratory drug reimbursement), Alimentary tract and 
metabolism (16%), Sensory organs (7%), Genito - urinary system and sexual hormones (6%) and Nervous system (5%). It was 
found no correlation between the number of COPD outpatients and non-respiratory drug reimbursement.  Non-respiratory 
drugs used in insured COPD outpatients are associated with considerable cost and they should be considered when estimating 
economic burden of COPD. Drugs acting in cardiovascular system and those used in diabetes have the most increased cost 
among them.  
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1. Introduction 
 
Most Chronic Obstructive Pulmonary Disease (COPD) patients suffer from other chronic medical conditions as well.1,2 
These conditions that are common at any severity of COPD3 are called comorbidities. Frequent comorbidities of patients 
with COPD include arthritis, cardiac disorders, hypertension, diabetes mellitus, lipid disorders, psychiatric conditions, 
gastrointestinal diseases, cancer, and osteoporosis (Table 1). Although it is widely accepted that COPD is associated 
with certain comorbidities the precise prevalence varies largely among epidemiological studies.2 
 
Table 1. Chronic Obstructive Pulmonary Disease and the prevalence of common comorbidities (%) 
 
Source n Arthritis Cardiac HTN Diabetes Lipids Psych GI Cancer Osteoporosis 
van Manen and 
colleagues (4) 1,145 36 13 23 5 — 9 15 6 — 
Mapel and 
colleagues (5) 200 22 65 45 12 — 17 32 18 — 
Soriano and 
colleagues (6) 2,699 28 22 — — — 10 26 4 — 
Sidney and 
colleagues (7) 45,97 — 18 18 2 9 — — — — 
Walsh and 
Thomashow (8) 3 70 50 52 16 51 38 62 4 32 
Definition of abbreviations: — = no available data; GI = gastrointestinal disturbances; HTN = hypertension 
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Unfortunately, the presence of both COPD and other comorbidities is often ominous and contributes significantly to poor 
health outcomes.9,10 In fact, numerous studies have suggested that comorbidities are a common cause of or contributor 
to COPD hospitalizations.11 In a study of over 45.000 patients with COPD, heart failure was the leading cause of 
hospitalization, followed by myocardial infarction and stroke.7 Kinnunen and colleagues found that comorbidities were 
associated with an increased duration of COPD hospitalizations; the mean length-of-stay in patients without comorbidity 
was 7.7 days compared with 10.5 days if a concurrent disease was present.12 So these comorbid conditions not only 
cause hospitalization, but also influence the length of hospital stay of patients with COPD.   
Furthermore, some studies evaluating the cause of death in COPD suggest that patients with COPD are more 
likely to die of comorbid conditions rather than COPD, with most deaths from cardiovascular disease or malignancy 
(Table 2), although this varies with the severity of COPD. 
 
Table 2. Reported causes of mortality in patients with Chronic Obstructive Pulmonary Disease (%) 
 
Author Site Patients with COPD Dying
Cause: 
COPD (%)
Cause: 
Cardiovascular (%)
Cause: 
Malignancy (%) 
Cause: Other 
Respiratory (%) 
Camilli and colleagues (13) Tucson 86 23 42 9 26 
Huiart and colleagues (14) Canada 2.000 14 38  
Anthonisen and colleagues (15) United States 149 < 15 25 60  
Keistinen and colleagues (16) Europe 973 22 37 21 4 
Vilkman and colleagues (17) Europe 1.070 30 37 20  
 
Therefore, comorbidities should be looked for routinely, and treated appropriately, in any patient with COPD1, as they 
contribute to impared clinical course and poor prognosis of COPD patients. COPD patients in general take a large 
number of drugs. Polypharmacy that characterizes these patients consists of  respiratory drugs, especially inhaled ones 
needed for COPD treatment, and non-respiratory drugs used for the treatment of multiple extra-pulmonary conditions that 
accompany COPD.  
Insured Albanian outpatients with COPD also are treated with numerous non-respiratory drugs. These medicines 
add to the daily-cost of COPD care. As the costs of reimbursed drugs are affordable totally or partially by the Health 
Insurance Institute, this study evaluates the costs of all drugs used from Albanian insured outpatients with COPD over a 
year and highlights the impact of non-respiratory drugs. 
 
2. Materials and Methods 
 
This retrospective study was conducted using Albanian Health Insurance Institute database. This institute was unique in 
Albania as a single-payer and involved all insured population. Its database contained data recorded from reimbursed 
medical prescriptions. The diagnosis codes, according to the International Classification of Diseases, Ninth Revision 
(ICD-9), insured outpatient codes, drug codes and drug costs were some important data of the reimbursed prescriptions 
which were recorded in every case in the Health Insurance Institute database. Drug code was created by Health 
Insurance Institute and it was associated with specific Anatomical Therapeutic Chemical (ATC) drug code in the 
database. The costs of reimbursed drugs were initially calculated by pharmacists based on the prices of reimbursed drug 
list published by Health Insurance Institute. All costs were expressed in Albanian currency (Lek). The costs paid by 
outpatients’ pocket for drugs which were partially reimbursed by Health Insurance Institute were not included in this study 
because of their little influence. 
First of all, insured COPD outpatients were identified using ICD-9 codes. Information about reimbursement of all 
drugs used from these outpatients in 2012 was then analyzed using international ATC system classification.  
This classification divides the drugs in groups at five different levels according to the organ or system on which 
they act and according to their chemical, pharmacological and therapeutic properties.18,19 
All reimbursed drugs and their costs were divided according to the first level (main anatomical group) and the 
second level (main therapeutic group) of ATC classification and the results were expressed as percentage of total costs. 
It was used Microsoft Office Excel Program  for all calculations. 
Furthermore, Pearson correlation coefficient was computed and a significance test was conducted  to found out 
whether the number of insured COPD outpatients and the costs of non-respiratory drugs used from them were correlated.  
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3. Results  
 
Total cost of respiratory and non-respiratory drugs reimbursed for Albanian outpatients with COPD was approximately 
224 mln Lek in 2012. 124 mln Lek (55%) were expended for respiratory drugs and 100 mln (45%) was the reimbursement 
of non-respiratory drugs used in the same outpatients for the treatment of comorbidities (Figure 1).  
 
 
 
Figure 1. Costs (%) of respiratory and non-respiratory drugs used from Albanian insured outpatients with COPD in 2012 
 
Among non-respiratory drugs higher costs were for the ones acting on: Cardiovascular system with C code (57% of non-
respiratory drug cost), Alimentary tract and metabolism with A code (16%), Sensory organs with S code (7%), Genito 
urinary system and sex hormones with G code (6%) and Nervous system with N code (5%) (Figure 2). 
 
 
 
Figure 2. Costs (%) of reimbursed non-respiratory drugs used in ambulatory COPD in 2012 according to ATC anatomical 
groups 
 
Drugs belonged to C09 and C08 therapeutic groups according to ATC classification had higher costs among 
cardiovascular ones (Table 3).  
 
Table 3. Costs (%) of reimbursed cardiovascular drugs used in COPD in primary care in 2012 according to ATC 
therapeutic groups 
 
Therapeutic groups Annual Costs (%)
C01 - Cardiac Therapy 8
C02 - Antihypertensives 4
C03 - Diuretics 9,5
C07 - Beta Blocking Agents 10,5
C08 - Calcium Channel Blockers 25
C09 - Agents Acting on the Renin-Angiotensin System 38
C10 - Lipid Modifying Agents 5
 
80% of total cost of reimbursed medications acting on alimentatry tract and metabolism belonged to antidiabetics with 
ATC code A10.(Figure 3).  
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Figure 3. Costs (%) of reimbursed drugs acting on alimentary tract and metabolism and used in COPD in primary care in 
2012 according to ATC therapeutic groups 
 
Only ophthalmologicals were used for the treatment of sensory organs diseases associated with COPD.  Costs of 
alfuzosine, tamsulosine, terazosine and finasteride drugs reimbursed for the treatment of benign prostatic hypertrophy 
represented 70% of annual cost of drugs acting on genito urinary system and sex hormones prescribed in COPD 
outpatients in 2012 (Table 4).  
 
Table 4.  Costs (%) of reimbused drugs acting on genito urinary system and sex hormones used in COPD in primary care 
in 2012 according to ATC therapeutic groups 
 
Therapeutic groups Annual Costs (%)
G01 - Gynecological Antiinfectives and Antiseptics 1
G03 - Sex Hormones and Modulators of the Genital System 28
G04 - Urologicals 71
G04B - Other urologicals, incl. antispasmodics 1
G04C - Drugs used in benign prostatic hypertrophy 70
 
Among drugs acting on the nervous system, most costly were the ones classified in N05A therapeutic subgroup–
antipsychotics. Antiparkinson and antiepileptic drugs also had high reimbursed costs, whereas all psychoanaleptics used 
in COPD were antidepressants (Table 5).  
 
Table 5. Costs (%) of reimbused drugs acting on nervous sytem used in COPD in primary care in 2012 according to ATC 
therapeutic groups  
 
Therapeutic group Annual Costs (%)
N02 - Analgesics 11
N03 - Antiepileptics 15
N04 – Antiparkinson Drugs 26
N05 - Psycholeptics 41
N05A - Antipsychotics 36
N05B - Anxiolytics 5
N06 - Psychoanaleptics
(N06A - Antidepressants) 7 
 
There was no significant correlation between the number of COPD outpatients and the reimbursement cost of  non-
respiratory drugs used for the treatment of COPD comorbidities. 
 
4. Discussion 
 
Albanian insured outpatients with COPD were exposed to many different non-respiratory drugs showing the presence of 
other coexisting conditions in the same patients. As a result, non-respiratory drugs had a considerable cost with 45% of 
the total drug cost reimbursed for COPD outpatients in 2012. In fact, concomitant comorbidites among COPD patients are 
associated with elevated healthcare costs.20,21 Medications used for the treatment of such comorbidities are only one of 
the components contributing to these elevated costs.  
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More than half of non-respiratory drug reimbursement was paid  for cardiovascular drugs. Several studies suggest 
that cardiovascular diseases (CVD) are more frequent in COPD patients than in general population and may represent a 
burden greater than that of lung disease itself (Burney et al 2003; Holguin et al 2005; Huiart et al 2005).22 Cardiovascular 
co-morbidity existed in 13% - 65% of COPD subjects in different studies (Table 1) and is probably the main comorbidity in 
COPD (Fabbri et al, 2008; Soriano et al, 2005). 
On the other hand, antidiabetics represented 80% of the cost of drugs acting on alimentary tract and metabolism, 
because diabetes mellitus frequently is associated with COPD. Large population studies show that there is an increased 
prevalence of diabetes among COPD patients (relative risk 1.5-1.8), even in patients with mild disease.23,24 
Glaucoma, prostate cancer, Parkinson’s disease and mental disorders especially depression and anxiety are also 
other reported comorbidities of patients with COPD. This explains the significant costs of ophtalmologicals, drugs used in 
benign prostatic hypertrophy and drugs acting on the nervous system as medications used for the treatment of such 
comorbidities.  
Mood disorders, including depression and anxiety, are more prevalent in patients with COPD than in the general 
population.25 However, anxiety and depressive disorders are underrecognized (< 40%) and undertreated (approximately 
30%) in patients with COPD.26 
So the results about most costly non-respiratory drugs used in insured COPD outpatients in Albania, in general are 
in agreement with findings of numerous studies regarding the patterns of non-pulmonary comorbidities  in COPD and the 
drugs used for their treatment. 
Studies often are focused only on the impact of drugs used for the main disease which is COPD in this case. In this 
context, the costs evaluation of reimbursed drugs used for treating associated conditions of COPD becomes important, 
as these costs have not been before the object of any study in Albania. 
There appear to be a number of mechanisms by which co-morbid conditions arise in patients with COPD other 
than by chance. The first of these is sharing of common risk factors. These include poor socioeconomic status, smoking 
and age which are clearly risk factor for a large range of conditions. Another mechanism is the increasingly well described 
systemic effects of COPD (Fabbri and Rabe 2007). This systemic inflammation is now thought to impact on extra-
pulmonary organs such the heart and blood vessels as well as the metabolic system. In addition, the effects of COPD 
increases the risks of other conditions with breathlessness, inactivity, and exacerbations resulting in depression, anxiety, 
and inactivity with resulting osteoporosis risk ad muscle loss. Finally, COPD treatment may in itself increase the risk of 
other conditions particularly those related to oral steroid usage.27 
The absence of correlation between the number of COPD outpatients and costs of non-respiratory drugs used from 
them may be explained by the fact that prevalence of comorbidities varies considerably in different populations with 
COPD.  
At last, it should be taken in consideration that only reimbursed drugs have been the object of this study. So it can 
be supposed that the impact of all non-respiratory drugs, reimbursed and non-reimbursed, and which are prescribed for 
all COPD outpatients, with and without health insurance, could be a little bit different from the results of this study. 
Moreover, relating to the limited healthcare resources, cost-effective therapies should be prescribed for COPD and its 
comorbidities as well. This suggestion is especially valuable for the care management of COPD patients with specific and 
frequent comorbidities treated with most costly drugs. 
 
5. Conclusion  
 
Reimbursed non-respiratory drugs are frequently used for the treatment of COPD comorbidities in primary care and their 
economic impact is considerable. Cardiovascular drugs and those used in diabetes mellitus have the most increased 
cost. As a result, not only respiratory drugs used for the treatment of COPD as the main disease, but also non-respiratory 
drugs used for the treatment of COPD extra-pulmonary comorbidities should be considered when evaluating the 
economic burden of COPD. Moreover, considering the limited health care resources it is important to use cost-effective 
therapies not only for COPD, but also for the treatment of its different comorbidities. This suggestion is especially 
valuable for care management of COPD patients with specific and frequent comorbidities treated with most costly drugs. 
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